Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Aurinia Pharmaceuticals ( (AUPH) ) is now available.
Aurinia Pharmaceuticals Inc. announced a leadership change with Board Chair Kevin Tang succeeding Peter Greenleaf as Chief Executive Officer, while Greenleaf will stay on as a consultant to support the transition. The company emphasized that Greenleaf’s seven-year tenure helped position Aurinia strongly, with LUPKYNIS gaining traction as a standard treatment for lupus nephritis and lead pipeline candidate aritinercept progressing rapidly in clinical development.
In conjunction with the CEO transition, Aurinia appointed Ryan Cole as Chief Operating Officer, Michael Hearne as Chief Financial Officer and Thomas Wei as Chief Scientific Officer, while confirming that Stew Kroll and Stephen Robertson will remain Chief Development Officer and General Counsel. The broadened executive team signals a push to consolidate the company’s commercial momentum and advance its autoimmune pipeline, underscoring Aurinia’s intent to strengthen operations and scientific leadership as it targets further growth in its niche markets.
The most recent analyst rating on (AUPH) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
The score is driven primarily by the improved fundamentals (revenue scale-up, strong cash generation, and low leverage) and a generally positive earnings call with double-digit 2026 growth guidance. These strengths are tempered by weak technical signals and uncertainties around the sustainability of reported profitability given the material one-time tax benefits, alongside competitive and regulatory risks.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its flagship product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis in the U.S., and it is also developing aritinercept, a dual BAFF/APRIL inhibitor, for potential use in other autoimmune indications.
Average Trading Volume: 979,001
Technical Sentiment Signal: Buy
Current Market Cap: $1.86B
For an in-depth examination of AUPH stock, go to TipRanks’ Overview page.